Skip to content

Fluval AB Vaccine Serologic Clinical Trial

Fluval AB Vaccine Serologic Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001600-12-HU
Enrollment
Unknown
Registered
2004-07-12
Start date
2004-09-20
Completion date
Unknown
Last updated
2015-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunization of healthy people against influenza virus infections.

Interventions

Trade Name: Fluval AB vaccine Product Name: Fluval AB vaccine Pharmaceutical Form: Injection* INN or Proposed INN: vaccinum inactivatum influenzae Other descriptive name: Influenza A/New Caledonia/20/

Sponsors

OMNINVEST Kft.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy adult volunteers above 18 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Allergy on any ingredient, pregnancy, age under 18 years

Design outcomes

Primary

MeasureTime frame
Main Objective: Verification of the fact that in consequence of the vaccination ratio of seroconversion was greater than 30-40 % (in dependence of the age category);Secondary Objective: Verification of the fact that in consequence of the vaccination increase of geometric mean titer was greater than 2 - 2,5 (in dependence of the age category);Primary end point(s): Verification of the fact that in consequence of the vaccination ratio of seroconversion was greater than 30-40 % (in dependence of the age category). Verification of the fact that in consequence of the vaccination increase of geometric mean titer was greater than 2 - 2,5 (in dependence of the age category).

Countries

Hungary

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026